METHOD OF VISUALIZING A BRIDGE THERAPY PROCESS

• US 20140118356A1
• Filed: 06/12/2012
• Published: 05/01/2014
• Est. Priority Date: 06/16/2011
• Status: Active Grant

• Current Assignee: Koninklijke Philips N.V.
• Original Assignee: Koninklijke Philips N.V.
• Inventors: van Ooijen, Henik Jan, van Den Ham, Rene, Bakker, Bart
• Granted Patent: US 9,788,798 B2
• Time in Patent Office: Days
• US Class Current: 345/440
• CPC Class Codes: A61B 5/02028 Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
• CPC Class Codes: A61B 5/02042 Determining blood loss or bleeding, e.g. during a surgical procedure
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 5/7278 Artificial waveform generation or derivation, e.g. synthesising signals from measured signals A61B5/327 takes precedence
• CPC Class Codes: A61B 5/742 using visual displays A61B5/339 takes precedence
• CPC Class Codes: A61B 5/7475 User input or interface means, e.g. keyboard, pointing device, joystick
• CPC Class Codes: G16B 45/00 ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
• CPC Class Codes: G16B 5/30 Dynamic-time models
• CPC Class Codes: G16H 10/40 for data related to laboratory analysis, e.g. patient specimen analysis
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 40/60 for the operation of medical equipment or devices
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

Claims

1. Method of visualizing a bridge therapy process, the method comprising the steps of:

receiving coagulation data describing a haemostatic situation of a blood circulation of a patient,

displaying the coagulation data to a user by means of an graphical representation,

displaying a first value measured by a first type of blood test, which first value indicates a first effect of a heparin like drug on the haemostatic situation,

simultaneously to the displaying of the first value displaying a second value measured by a second type of blood test, which second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation, and

wherein the first and second values describe the haemostatic situation of the blood circulation at a first point in time.

2. The method according to claim 1, further comprising the steps of:

displaying a third value measured by the first type of blood test, which third value indicates a third effect of a heparin like drug on the haemostatic situation,

simultaneously to the displaying of the third value displaying a fourth value measured by the second type of blood test, which fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation,

wherein the third and fourth values describe the haemostatic situation of the blood circulation at a second point in time, and

thereby displaying a time progression of the haemostatic situation.

3. The method according to claim 1,

wherein the first and second type of blood test are respectively and independently chosen from the group consisting of activated partial thromboplastine time (aPTT) test, anti-Factor 10a test, prothrombin time (PT) test, international normalized ratio (INR) test, a test indicating thrombosis or coagulation, a test indicating bleeding or anti-coagulation, a test indicating the haemostatic function.

4. The method according to claim 1, further comprising the step of:

calculating a prediction of the haemostatic situation of the blood circulation by a mathematical representation of the blood circulation

5. The method according to claim 1, further comprising the step of:

calculating a prediction of the haemostatic situation of the blood circulation by combining a biochemical model of the blood circulation and a pharmacodynamical model of the blood circulation.

6. The method according to claim 5, further comprising the steps of:

calculating an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model, which results in a calculated pharmacodynamical effect.

7. The method according to claim 6, the method further comprising the steps of:

calculating a coagulation effect and/or a fibrin polymerization effect with the biochemical model based on the calculated pharmacodynamical effect, and

displaying a prediction value of the haemostatic situation,

wherein the prediction value is based on at least one of the calculated pharmacodynamical effect, the calculated coagulation effect, and the calculated fibrin polymerization effect.

8. The method according to claim 1, the method further comprising the step of:

automatically suggesting an application of an coagulant and/or an anti-coagulant.

9. The method according to claim 8,

wherein the step of automatically suggesting an application of an coagulant and/or an anti-coagulant is based on a calculated progression of the haemostatic situation.

10. User interface for visualizing a bridge therapy process, the user interface comprising:

a receiving arrangement configured to receive coagulation data describing a haemostatic situation of a blood circulation of a patient,

wherein the user interface is configured to display the haemostatic situation of said blood circulation,

wherein the user interface is configured to display a first value measured by a first type of blood test, which first value indicates a first effect of a heparin like drug on the haemostatic situation, and

wherein the user interface is configured to simultaneously display a second value measured by a second type of blood test, which second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation.

11. User interface according to claim 10

wherein the user interface is configured to display a third value measured by the first type of blood test, which third value indicates a third effect of a heparin like drug on the haemostatic situation at a second point in time,

wherein the user interface is configured to display a fourth value measured by the second type of blood test simultaneously to the first, second and third value, which fourth value indicates a fourth effect of a vitamin K antagonist type anticoagulant on the haemostatic situation at the second point in time, and

wherein the user interface is configured to display a time progression of the haemostatic situation by means of the first, second, third and fourth measured value.

12. User interface according to claim 10, the user interface further comprising:

a calculation arrangement, and

wherein the calculation arrangement is configured to calculate a prediction of the haemostatic situation of the blood circulation by using mathematical representation of the blood circulation or by a combining a biochemical model of the blood circulation and a pharmacodynamical model of the blood circulation.

13. User interface according to claim 10,

wherein the calculation arrangement is configured to calculate an effect of an anticoagulant drug during a predetermined time by using the pharmacodynamical model,

wherein the calculation arrangement is configured to generate a calculated pharmacodynamical effect, and

wherein the calculation arrangement is configured to use the calculated pharmacodynamical effect as an input for the biochemical model.

14. Program element for visualizing a bridge therapy process, which when being executed by a processor is adapted to carry out:

receiving coagulation data describing a haemostatic situation of a blood circulation,

displaying the coagulation data to a user by means of an graphical representation,

displaying a first measured value of a first type of blood test, which first measured value indicates a first effect of a heparin like drug on the haemostatic situation,

simultaneously to the displaying of the first measured value displaying a second measured value of a second type of blood test, which second measured value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation.

15. Computer readable medium in which a program element for visualizing a bridge therapy process is stored, which, when being executed by a processor is adapted to carry out:

receiving coagulation data describing a haemostatic situation of a blood circulation,

displaying the coagulation data to a user by means of an graphical representation,

displaying a first value measured by a first type of blood test, which first value indicates a first effect of a heparin like drug on the haemostatic situation,

simultaneously to the displaying of the first measured value displaying a second value measured by a second type of blood test, which second value indicates a second effect of a vitamin K antagonist type anticoagulant on the haemostatic situation.